Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of both the diseases, the efficacy of IL-1 blocking molecules in controlling these diseases, and will provide information suggesting that targeting IL-1β, in patients affected by both RA and T2D, may be a promising therapeutic choice.
|Numero di pagine||7|
|Rivista||Expert Review of Clinical Immunology|
|Stato di pubblicazione||Published - 2016|
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
Triolo, G., Guggino, G., Ciccia, F., Liakouli, V., Carubbi, F., Di Benedetto, P., Alvaro, S., Ruscitti, P., Berardicurti, O., Giacomelli, R., & Cipriani, P. (2016). IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? Expert Review of Clinical Immunology, 12, 849-855.